Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.Financial_Report.xls
10-K - FORM 10-K - Oncologix Tech Inc.oncologix8312012.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R12.htm
EX-21 - SUBSIDIARIES OF ONCOLOGIX TECH, INC. - Oncologix Tech Inc.oncologix8312012exh21.htm
EX-99 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Oncologix Tech Inc.oncologix8312012exh99.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER - Oncologix Tech Inc.oncologix8312012exh312.htm
EX-32.1 - CERTIFICATION - Oncologix Tech Inc.oncologix8312012exh321.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER - Oncologix Tech Inc.oncologix8312012exh311.htm
EX-32.2 - CERTIFICATION - Oncologix Tech Inc.oncologix8312012exh322.htm
v2.4.0.6
Consolidated Statements of Changes in Stockholders' Deficit (USD $)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit Prior to Reentering Development Stage
Deficit Accumulated Since Reentering the Development Stage on June 1, 2011
Non-Controlling Interest
Total
Beginning Balance, Value at Sep. 30, 2010 $ 262 $ 47,155 $ 57,177,033 $ (57,817,700)    $ (3,448) $ (596,698)
Beginning Balance, Shares at Sep. 30, 2010 261,762 47,155,815          
Issuance of stock purchased for cash, Shares    1,250,001          
Issuance of stock purchased for cash, Value    1,250 73,750          75,000
Stock based compensation       464          464
Net loss          (187,169)    (10) (187,179)
Ending Balance, Value at Jun. 01, 2011 262 48,405 57,251,247 (58,004,869)    (3,458) (708,413)
Ending Balance, Shares at Jun. 01, 2011 261,762 48,405,816          
Issuance of stock purchased for cash, Shares    2,500,000          
Issuance of stock purchased for cash, Value    2,500 97,500          100,000
Induced conversion expense - conversion notes payable       6,076          6,076
Cancellation of preferred shares for unit conversions, Shares (132,700)             
Cancellation of preferred shares for unit conversions, Value (133)    133            
Conversion of notes payable, Shares    92,998          
Conversion of notes payable, Value    94 3,626          3,720
Net loss             (48,427) (3) (48,430)
Ending Balance, Value at Aug. 31, 2011 129 57,563 57,697,233 (58,004,869) (333,982) (3,475) (587,401)
Ending Balance, Shares at Aug. 31, 2011 129,062 57,563,258          
Issuance of stock purchased for cash, Shares    1,875,000          
Issuance of stock purchased for cash, Value    1,875 73,125          75,000
Induced conversion expense - conversion notes payable       25,402          25,402
Conversion of notes payable, Shares    4,689,444          
Conversion of notes payable, Value    4,689 137,366          142,055
Loss on conversion of notes payable - related parties       92,758          92,758
Beneficial conversion feature notes payable       10,000          10,000
Stock based compensation               
Net loss             (285,555) (14) (285,569)
Ending Balance, Value at Aug. 31, 2012 $ 129            
Ending Balance, Shares at Aug. 31, 2012 129,062